MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will give the keynote: Future Innovations in Healthcare: From Dreaming to Community Health at the Pharma Market Research Conference (PMRC) from February 7-8, 2024 in Newark, NJ. "Since its beg ...

MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer, has joined the Company's Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the worl ...

MALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company received alignment from FDA on key aspects of the Phase 3 clinical trial design to assess the safety and efficacy of OCU400 in patients with RHO and other gene mutations associated with Retinitis Pigmentosa (RP). "This news brings us even closer to fulfil ...

Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Tiffany Hamilton - Head of Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer and Co-Founder Michael Breininger - Corporate Controller, Interim Chief Accounting Officer Arun Upadhyay - Chief Scientific Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Operator Good morning and welcome to Ocugen’s Third Quart ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36751 _____________ ...

Ocugen Inc. (NASDAQ:OCGN) Q2 2023 Earnings Conference Call August 22, 2023 8:30 AM ET Company Participants Shankar Musunuri - Chief Executive Officer Arun Upadhyay - Chief Scientific Officer Tiffany Hamilton - Head of Corporate Communications Conference Call Participants Jennifer Kim - Cantor Fitzgerald Swayampakula Ramakanth - HC Wainwright Robert LeBoyer - Noble Capital Markets Daniil Gataulin - Chardan Capital Markets Operator Good morning and welcome to Ocugen’s second quarter 2023 financial results an ...

Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36751 __________________ ...

Start Time: 08:30 January 1, 0000 9:05 AM ET Ocugen, Inc. (NASDAQ:OCGN) Q1 2023 Earnings Conference Call May 05, 2023, 08:30 AM ET Company Participants Shankar Musunuri - Chairman, CEO and Co-Founder Quan Vu - CFO and Chief Business Officer Sharon Choe - Head of IR Conference Call Participants Jennifer Kim - Cantor Fitzgerald Jonathan Aschoff - ROTH Capital Partners Uy Ear - Mizuho Securities Robert LeBoyer - Noble Capital Markets Swayampakula Ramakanth - H.C. Wainwright Daniil Gataulin - Chardan Operator G ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36751 _________________ ...

Ocugen, Inc. (NASDAQ:OCGN) Q4 2022 Earnings Conference Call February 27, 2023 8:30 AM ET Company Participants Tiffany Hamilton - Head of Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Jessica Crespo - Chief Accounting Officer & Senior Vice President, Finance Conference Call Participants Uy Ear - Mizuho Securities Jennifer Kim - Cantor Fitzgerald Jonathan Aschoff - ROTH Capital Partners Robert LeBoyer - Noble Capital Markets Sean Lee - H.C. Wainwright Daniil Gataul ...